Aim­mune's PhI­II peanut al­ler­gy study wows on the pri­ma­ry end­point, set­ting up FDA pitch -- and shares slide

Four months af­ter DBV Tech­nolo­gies stock was crushed by a shaky set of piv­otal da­ta for its peanut al­ler­gy drug, ri­val Aim­mune Ther­a­peu­tics $AIMT says its Phase III has come through with a promis­ing set of re­sults. And the win sets up an FDA ap­pli­ca­tion lat­er this year for the pi­o­neer­ing drug, with a Eu­ro­pean pitch to fol­low soon af­ter.

Of the 554 pa­tients in the study, 67.2% of the group in the AR101 drug arm were able to tol­er­ate at least a 600 mg dose of peanut pro­tein, pro­tect­ing them from a po­ten­tial­ly dead­ly al­ler­gic re­ac­tion against a small ex­po­sure. In the place­bo arm, on­ly 4% of the 4- to 17-year-olds in the study could say the same.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.